NCT00995969

CT 327 in the Treatment of Psoriasis Vulgaris

A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a Topical Cream Formulation of Pegylated K252a, When Administered Twice Daily for Eight Weeks to Patients With Mild to Moderate Psoriasis Vulgaris

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Creabilis SA · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate psoriasis vulgaris (PV). Patients will be treated twice daily for 8 weeks on specific lesions of PV and safety and symptoms of PV will be assessed throughout the treatment period.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	placebo	1.0 g (w/w) placebo cream applied to both target lesions twice daily
DRUG	CT 327	1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily

Timeline

• Start date: 2010-03-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2009-10-16
• Last updated: 2011-02-10

Locations

12 sites across 3 countries: United States, Switzerland, United Kingdom